Medigene announces Veregen® to be launched in the Czech Republic, Poland, Hungary, and Slovakia
11 December 2013 - 5:30PM
Medigene AG / Medigene announces Veregen® to be launched in the
Czech Republic, Poland, Hungary, and Slovakia . Processed and
transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
- Market launches to be
initiated in Q1 2014
- Veregen®, an extract of green
tea leaves, included into new treatment guidelines for genital
warts
Martinsried/Munich, 11 December 2013. Medigene AG
(MDG1, Frankfurt, Prime Standard) announces that the market launch
of Veregen® ointment for
the treatment of genital warts in the East European countries the
Czech Republic, Poland, Hungary, and Slovakia is scheduled to be
initiated by the company's marketing partner NORDIC Pharma, s.r.o.
in the first quarter 2014.
Professor Jana Hercogová,
president of European Academy of Dermatology and Venereology (EADV)
will introduce the new guidelines for the treatment of condylomata
accuminata (genital warts) and inform about the new treatment
options, including an extract of green tea leaves, during the
Annual Congress of the Hungarian Dermatological Society in Budapest
on December 14, 2013. NORDIC Pharma will have an exhibition booth
to introduce Veregen® ointment
(extract of green tea leaves) to the medical community.
Veregen® is already
available in the USA, Germany, Austria, Switzerland, Spain, Serbia,
the Netherlands and Taiwan. Market approvals for Veregen®
have been granted in a number of other countries. Several marketing
agreements have been concluded in Europe, Asia, and America.
Medigene is planning to continue this global licensing strategy to
further exploit the product's market potential.
About Veregen®:
Veregen®, a topical
treatment for external genital or perianal warts, contains a
concentrate of catechins with a complex defined composition
extracted from green tea leaves. In its current treatment
guidelines for sexually transmitted diseases, the US Center for
Disease Control and Prevention recommends Sinecatechins 15%
ointment (Veregen®) as a
possible option for treating genital warts. In addition,
Sinecatechins 10% & 15% ointment (Veregen®) has
been included in the current European guideline on the treatment of
genital warts, the 2012 European Guideline for the Management of
Anogenital Warts.
About NORDIC
Pharma: The Nordic Group is a privately owned,
fast-growing, fully integrated, pan-European Pharmaceutical Group
with a strong emphasis on quality products and services that cater
to the special needs of each client and patient. The Nordic Group
originated in 1995 with the establishment of the first Nordic
organisation in Scandinavia. In the years that followed, the Nordic
Group gradually expanded its geographical implantation throughout
Europe and significantly enlarged its range of activities. Today,
the Nordic Group continues to capitalise on its existing platform
of core competencies, products, services, and technologies to
develop the company in two specialised segments of the
pharmaceutical market: marketing and sales of specialty
pharmaceuticals and specialised pharmaceutical services which focus
on product development, manufacturing, supply logistics, and
regulatory activities. For more information, please visit
http://www.nordicpharmagroup.com/.
Medigene
AG is a publicly listed (Frankfurt: MDG1, prime standard)
biotechnology company headquartered in Martinsried near Munich,
Germany. Medigene focuses on clinical research and development of
novel drugs against cancer and autoimmune diseases. Medigene is the
first German biotech company to have revenues from a marketed
product, Veregen®, which is
distributed by partner companies. It has two drug candidates in
clinical trials, EndoTAG®-1 and
RhuDex®; and is
developing an innovative vaccine technology. Further information at
www.medigene.com.
This press
release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual
results achieved by Medigene may differ significantly from the
forward-looking statements made herein. Medigene is not bound to
update any of these forward-looking statements. Medigene®, Veregen®, EndoTAG® and RhuDex® are registered trademarks of
Medigene AG. These trademarks may be owned or licensed in select
locations only.
Contact
Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press
release distribution list, please go to:
www.medigene.de/unsubscribe
Press release as PDF
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medigene AG via Globenewswire
HUG#1748902
Meridian Gold (NYSE:MDG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Meridian Gold (NYSE:MDG)
Historical Stock Chart
From Dec 2023 to Dec 2024
